6月6日周五《新闻联播》要闻32条 智通财经6月6日电，今天《新闻联播》主要内容有： 1、习近平接受班禅额尔德尼·确吉杰布拜见； 2、习近平同美国总统通电话； 3、习近平向波兰当选总统纳夫罗茨基致贺电； 4、李强同加拿大总理通电话； 5、深入贯彻中央八项规定精神学习教育中央指导组工作座谈会召开； 6、加快发展首发经济 激发消费新活力； 7、各地多措并举稳外贸促发展； 8、【在希望的田野上·三夏时节】智慧气象"抢"出麦收加速度； 9、企业稳岗扩岗 增加就业渠道； 10、国务院新闻办召开"新征程上的奋斗者"中外记者见面会； 11、第9届中国—南亚博览会将在昆明举办； 12、热地同志逝世； 13、中国仓储指数连续七个月运行在扩张区间； 14、国家航天局发布天问二号探测器圆形太阳翼展开图片； 15、我国成功发射卫星互联网低轨卫星； 16、我国第9个文化和自然遗产日主题发布； 17、教育部部署开展2025届高校毕业生就业"百日冲刺"行动； 18、"十四五"期间我国眼健康服务取得长足进步； 19、我国全面推进分娩镇痛服务； 20、广东海洋生产总值突破2万亿元； 21、包银高铁内蒙古段铺轨完成； 22、各地少数民族群众欢度 ...

Policy Developments - The National Healthcare Security Administration has revised the medical price and procurement credit evaluation system to combat commercial bribery and encourage integrity among pharmaceutical companies [2][3] - The revised system aims to increase the cost of dishonesty for companies and promote compliance, quality improvement, and effective market participation through collective procurement and national negotiations [2][3] Industry Updates - The internal whistleblower reward system for drug and medical device quality safety has been announced, incentivizing individuals who provide clear evidence of violations that lead to administrative penalties or criminal prosecution [4] - A notification has been issued to promote pain relief services during childbirth across various medical institutions, with goals set for 2025 and 2027 to ensure comprehensive service availability [5] Company News - Puluo Pharmaceutical has received approval for the listing application of Succinic Acid Desvenlafaxine, a third-generation antidepressant for treating major depressive disorder [7] - China Pharmaceutical has obtained a drug registration certificate for Sulfhydryl Clopidogrel Tablets, aimed at secondary prevention of atherosclerotic thromboembolic events in specific patient groups [8] - Shanghai Sipurei Pharmaceutical Technology has completed over 200 million RMB in angel round financing, with funds allocated for preclinical and early clinical development [11] - Kelun Pharmaceutical's subsidiary plans to raise approximately 1.943 billion HKD through a share placement to support product development and operational needs [12] - Merck KGaA has entered a strategic partnership with Zai Lab to commercialize a recombinant human thyroid-stimulating hormone in mainland China [14] - China National Pharmaceutical Group has established a technology innovation research institute with a registered capital of 1 billion RMB, focusing on various research and development activities [15] Management Changes - Tongrentang Technology announced the resignation of its chairman and general manager due to work changes, indicating potential shifts in company leadership [17]

国家卫生健康委会同国家中医药局、国家疾控局今天发布《关于全面推进分娩镇痛工作的通知》，推动 综合医院、妇产专科医院、妇幼保健机构等提供产科医疗服务的医疗机构广泛开展分娩镇痛服务，不断 提高医疗服务舒适化水平。提出：到2025年底，开展产科医疗服务的三级医疗机构全部能够提供分娩镇 痛服务；到2027年，开展产科医疗服务的二级以上医疗机构全部能够提供分娩镇痛服务。(央视新闻) ...